Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Primary tabs

  • View(active tab)

Upcoming Events

Thumbnail
February 15, 2019

Upcoming events – Pivotal data for Galapagos and Cara

Galapagos will discover if filgotinib can hang on to its reputation as one of the safest Jak inhibitors in the industry, while Cara is itching for pivotal trial success with intravenous Korsuva.

Thumbnail
February 08, 2019

Upcoming events – cancer readouts for Merck & Co and Seattle

Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.

Article image
Vantage logo
February 07, 2019

Go or no go? Sanofi’s Cablivi leads February’s approvals charge

Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.

Article image
Vantage logo
February 01, 2019

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.

Article image
Vantage logo
January 25, 2019

Upcoming events – Allergan and Lundbeck await depression and mania data

Allergan needs a win with rapastinel, while Lundbeck's chief exec faces her second clinical challenge.

Article image
Vantage logo
January 18, 2019

Upcoming events – Allergy's long-awaited birch data and Caladrius's Treg test

Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…

Article image
Vantage logo
January 11, 2019

Upcoming events – Jazz and Macrogenics look to phase III readouts

Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.

Article image
Vantage logo
January 04, 2019

Upcoming events – pivotal data loom for Novavax and Mallinckrodt

Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…

Article image
Vantage logo
January 03, 2019

Go or no go? Immunomedics, Exelixis and Alkermes await FDA letters

Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.

Article image
Vantage logo
December 21, 2018

Upcoming events – Phase III readouts loom for Urogen and Mediwound

Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.

Article image
Vantage logo
December 14, 2018

Upcoming events – Verona waits to exhale and a new test for Alexion

Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 13, 2018

Vantage 2019 Preview

November 27, 2018

First-line lung cancer: can Keytruda be stopped?

Editor's Picks

Vantage logo
January 22, 2019

Gene therapy: how much will it cost patients?

Vantage logo
January 25, 2019

Last year’s new medicines reveal strong commercial promise and some novelty

Vantage logo
January 21, 2019

Roche dominates 2019’s big patent expiries

Vantage logo
January 24, 2019

Bristol makes investors squirm a little more

Vantage logo
January 22, 2019

J&J’s dour outlook spells trouble for biopharma

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.